Teladoc Health, Inc.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US87918A1051
USD
7.78
0.25 (3.32%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Teladoc Health, Inc. stock-summary
stock-summary
Teladoc Health, Inc.
Pharmaceuticals & Biotechnology
Teladoc Health, Inc. provides virtual healthcare services. The Company provides virtual access to care with a portfolio of services and solutions, which includes various medical subspecialties from non-urgent, episodic needs, such as flu and upper respiratory infections, to chronic, complicated medical conditions, such as cancer and congestive heart failure. It provides virtual healthcare services on a business-to-business (B2B) basis to its clients and provides services to consumers directly and through channel partners. The Company’s consumer brands, including Teladoc, Advance Medical, Best Doctors, BetterHelp and HealthiestYou, provides access to advice and resolution to a range of healthcare needs. Its technology enables consumers to manage their own electronic medical records. It also provides access to a message center, provider finder, image upload capability and enable real-time sharing capabilities with providers that includes visit scheduling.
Company Coordinates stock-summary
Company Details
2 Manhattanville Rd Ste 203 , PURCHASE NY : 10577-2118
stock-summary
Tel: 1 203 6352002
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 71 Schemes (36.25%)

Foreign Institutions

Held by 217 Foreign Institutions (20.52%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. David Snow
Independent Chairman of the Board
Mr. Jason Gorevic
Chief Executive Officer, Director
Mr. Christopher Bischoff
Director
Ms. Karen Daniel
Director
Ms. Sandra Fenwick
Director
Mr. Hemant Taneja
Director
Mr. Glen Tullman
Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
632 Million
(Quarterly Results - Jun 2025)
Net Profit:
-33 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 1,385 Million (Small Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.23

stock-summary
Return on Equity

-8.67%

stock-summary
Price to Book

0.97